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Introduction {#sec1}
============

Significant advances in cell-based therapies, particularly in the liver, represent promising alternatives to whole-organ transplantation. Cell transplantation has several benefits over organ transplantation, including the use of one organ for several patients, and the procedure itself is generally less invasive. Although significant progress has been made, immune system clearance and cell-based therapy reliance upon organ donations are significant limitations. As a result, obtaining a potentially unlimited supply of somatic cells from defined genetics for cell-based therapy is an intense area of study.

Pluripotent stem cells are particularly promising cell types, possessing the ability to self-replicate and differentiate into all cell types in the body, including hepatocytes ([@bib41]). This promises in theory an "off-the-shelf" alternative to donated tissue. Differentiation procedures have advanced over the last decade, and efficient protocols to generate stem cell-derived hepatocyte-like cells (HLCs) from either human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) now exist ([@bib21], [@bib14], [@bib15], [@bib16], [@bib3], [@bib8], [@bib1], [@bib40], [@bib49], [@bib36], [@bib32], [@bib31], [@bib54], [@bib55], [@bib27], [@bib45], [@bib43]). These procedures utilize growth factors, mimicking each stages of embryonic development, and can deliver homogenous populations of HLCs. Although these prototype systems have provided confidence in pluripotent stem cell technologies, their amenability to defined scale-up with clinical-grade hESC lines has not been achieved.

HLCs derived from pluripotent stem cells have shown significant promise in vitro, accurately modeling human drug exposure ([@bib27], [@bib44], [@bib18], [@bib52]). HLCs have also been employed to study the hepatitis C virus life cycle ([@bib53], [@bib34], [@bib55], [@bib6]) and, more recently, the malaria parasite ([@bib30]). HLCs have also been derived from patients with monogenic metabolic liver diseases and have been shown to recapitulate features of α1-antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease ([@bib32]). The ability to generate population-specific HLCs that accurately represent adult liver tissue has significant implications in the drug development process and in stratifying patient healthcare.

Despite these advances, HLCs derived from pluripotent stem cells still display an immature phenotype ([@bib13], [@bib9]). This phenotypic immaturity has contributed to the limited the use of stem cell-derived hepatocytes for clinical application ([@bib35]). Efforts to address this have utilized natural and synthetic culture substrates to improve mature hepatocyte function and enhance stability ([@bib46], [@bib19], [@bib51]). Other studies have used small molecules to replace growth factors to drive down the cost of the method ([@bib14], [@bib15], [@bib37]); however, those published methods both still rely upon the use of undefined components, highlighting the need to develop defined systems.

A critical component of in vitro maintenance and differentiation systems is extracellular matrix (ECM) support. The ECM elicits profound effects on cell behavior. In the human stem cell self-renewal and differentiation fields, the mouse sarcoma-derived Matrigel represents the most extensively used ECM. Although Matrigel has undoubtedly been enabling for the stem cell field, its relatively undefined nature and significant batch-to-batch variability results in difficulties to generate reliable, reproducible cultures of HLCs. Moreover, if HLCs are to be utilized clinically, then this process must meet good manufacturing process (GMP) guidelines. To comply with this, products containing animal derivatives are strictly controlled. Therefore, to overcome variability, and in an effort to define our differentiation process, we employed two recombinant full-length human laminins and compared those with Matrigel in three hESC lines, two of which are available at GMP-grade.

The laminins used in our system were selected because of their importance in the developing embryo ([@bib7], [@bib28]), the regenerating liver ([@bib26], [@bib5]), and the liver stem cell niche ([@bib47], [@bib23]). Additionally, the laminins employed in this study are known to support the clonal expansion of hESCs ([@bib33]) and drive endodermal differentiation ([@bib48]) and liver stem cell differentiation ([@bib45]), making them ideal candidate substrates for our purposes. Although endoderm and liver stem cell differentiation has been achieved, neither of the laminin matrices employed, in isolation or mixed format, have been shown to support hepatocyte differentiation from research- and GMP-grade hESC lines.

Utilizing pure laminin 521 (L521) and the blend of laminins 521 and 111 as substrates for hESC-derived differentiation, we demonstrate efficient hepatocyte specification and significant improvements in cell function and phenotype. Furthermore, stem cell-derived hepatocytes derived on laminin surfaces formed organized structures, and their gene regulatory networks were closer to that of freshly isolated human hepatocytes. We believe that these studies represent a significant advance toward the large-scale production of clinical-grade and quality-assured human hepatocytes from GMP hESCs.

Results {#sec2}
=======

Differentiation of Pluripotent Stem Cells Toward Hepatocytes {#sec2.1}
------------------------------------------------------------

hESCs were replated onto Matrigel and wells coated with pure laminin 521 and the laminin 521:111 mix (1:3 ratio, hereafter referred to as laminin 111 mix \[L111\]). hESCs were differentiated using our standard protocol, outlined in [Figure 1](#fig1){ref-type="fig"}, and analyzed at key time points. hESCs on all three matrices adhered, proliferated, and differentiated into HLCs. Twenty-four hours after replating, hESCs were examined for characteristic colony morphology and stem cell-associated marker expression ([Figure S1](#mmc1){ref-type="supplementary-material"}). hESCs displayed the appropriate embryonic stem cell morphology, with subtle differences detected on each matrix ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Importantly, the majority of hESCs expressed the stem cell markers Oct4 and Nanog when attached to Matrigel (88.3% ± 4.8% and 86.7% ± 5.0%, respectively), laminin 521 (93.2% ± 5.9% and 88.7% ± 5.4%, respectively), and laminin 111 mix (93.8% ± 2.4% and 90.4% ± 3.5%, respectively) ([Figure S1](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). These results were corroborated by qPCR ([Figures 2](#fig2){ref-type="fig"}A and 2B).

Twenty-four hours after replating, differentiation was initiated using a serum-free procedure ([@bib43], [@bib4]). Cell extracts were collected, and mRNA was assessed at the denoted time points ([Figure 2](#fig2){ref-type="fig"}; [Table S2](#mmc1){ref-type="supplementary-material"}). All differentiation procedures delivered cell populations that transited from pluripotency, through definitive endoderm, to hepatoblast-like cells, and, subsequently, hepatocytes, as demonstrated by qPCR ([Figure 2](#fig2){ref-type="fig"}). The pluripotency-associated markers *OCT4* ([Figure 2](#fig2){ref-type="fig"}A) and *NANOG* ([Figure 2](#fig2){ref-type="fig"}B) decreased over time on all substrates. The endoderm-associated gene *FOXA2* peaked on all substrates on day 3 and then decreased thereafter ([Figure 2](#fig2){ref-type="fig"}C). Expression of *AFP* varied across all substrates ([Figure 2](#fig2){ref-type="fig"}D). Cells on Matrigel and laminin 521 followed the same trend in expression, peaking on day 9 and then decreasing on day 18. Conversely, cells on the laminin 111 mix gradually increased in *AFP* expression over time, peaking on day 18. *HNF4A* was detected as early as day 3 on all substrates ([Figure 2](#fig2){ref-type="fig"}E). By day 9, differences in expression patterns emerged. On Matrigel and laminin 521, *HNF4A* was highest on day 9 and decreased on day 18, whereas, on the laminin 111 mix, on day 18, *HNF4A* expression was increased. Variation in *HNF4A* gene expression was observed between experimental replicates. However, this did not appear to affect downstream differentiation and was not reflected in HNF4α protein levels ([Figures 3](#fig3){ref-type="fig"} and [6](#fig6){ref-type="fig"}).

Expression of *ALB* was upregulated from day 9 across all substrates ([Figure 2](#fig2){ref-type="fig"}F). Levels of *ALB* from days 9--18 saw the highest increase on the laminin 111 mix (∼10,000-fold), significantly higher than on Matrigel (p \< 0.001) and laminin 521 (p \< 0.001).

Human Embryonic Stem Cell-Derived Hepatoblast Specification {#sec2.2}
-----------------------------------------------------------

Although our previous data provided encouragement that stem cell differentiation was proceeding as we would expect, our next objective was to test the efficiency of the process on human recombinant laminin 521 and the laminin 111 mix in comparison with Matrigel ([Figure 3](#fig3){ref-type="fig"}). Human embryonic stem cell (ESC)-derived endoderm specification was measured using two commonly used endoderm-associated markers: FoxA2 and Sox17. The majority of cells on Matrigel, laminin 521, and laminin 111 mix were positive for FoxA2, with 82.8% ± 2.1%, 80.4% ± 3.5%, and 88.1% ± 2.3% cells positive, respectively ([Figure 3](#fig3){ref-type="fig"}A). Sox17 staining was more varied across the three matrices. It was lowest on Matrigel (74.8% ± 8.3%) and higher on laminin 521 (92.6% ± 1.8%) and the laminin 111 mix (87.2% ± 6.9%) ([Figure 3](#fig3){ref-type="fig"}B). As differentiation progressed and hepatic fate was specified (by day 9), cells began expressing high levels of hepatoblast markers. AFP was expressed in the majority of cells on Matrigel (90.8% ± 1.1%), laminin 521 (98.3% ± 0.9%), and the laminin 111 mix (95.3% ± 2.0%) ([Figure 3](#fig3){ref-type="fig"}C). The trend was similar for HNF4A, with the majority of cells expressing the transcription factor on Matrigel (88.5% ± 2.5%), laminin 521 (86.4% ± 2.3%), or the laminin 111 mix (85.9% ± 1.8%) ([Figure 3](#fig3){ref-type="fig"}D). CK19 expression was also observed in the majority of cells differentiated on Matrigel (96.8% ± 2.0%), laminin 521 (98.5% ± 1.0%), and the laminin 111 mix (97.2% ± 1.5%) ([Figure 3](#fig3){ref-type="fig"}E). Hepatoblast specification on all three matrices appeared to be equivalent and highly efficient, and the initial differences in hESC morphology observed on the three matrices did not appear to affect the kinetics or the efficiency of cellular differentiation. However, we did observe an ∼2-fold increase in cell size in HLCs differentiated on the laminin 111 mix and 521 substrates ([Figure 3](#fig3){ref-type="fig"}E, CK19).

Human Embryonic Stem Cell-Derived Hepatocyte Specification and Maturation {#sec2.3}
-------------------------------------------------------------------------

Post-hepatoblast specification, cell cultures were differentiated toward hepatocytes, and, on day 18, hepatocyte specification was assessed by immunostaining for albumin and E-cadherin. Notably, similar patterns of protein production in the Matrigel and laminin populations were observed ([Figure 4](#fig4){ref-type="fig"}). Albumin staining was detected in HLCs on Matrigel (91.6% ± 0.7%), laminin 521 (89.5% ± 8.7%), and the laminin 111 mix (91.3% ± 4.0%) ([Figure 4](#fig4){ref-type="fig"}A). Next, E-cadherin (E CAD) expression was assessed because of its importance in cell-to-cell contact ([@bib50]) and low-level expression in fetal hepatocytes ([@bib39]). On Matrigel and the laminin 111 mix, E-cadherin was expressed in 76.5% (± 0.7%) of cells and 73.7% (± 3.7%), whereas HLCs on laminin 521 were 67.4% (± 4.4%) positive ([Figure 4](#fig4){ref-type="fig"}B). Although immunostaining studies showed equivalence between the cell populations, differences in cell proliferation were observed on the different substrates. Of note, HLCs derived on Matrigel demonstrated an increase in the cell proliferation marker Ki67, with 29.8% (± 3.7%) of HLCs staining positive. This was in contrast to 17.4% (± 6.2%) of positive HLCs on laminin 521 and 15.9% (± 6.6%) on the laminin 111 mix ([Figure 4](#fig4){ref-type="fig"}C).

Human Embryonic Stem Cell-Derived Hepatocyte and Primary Hepatocyte Function {#sec2.4}
----------------------------------------------------------------------------

Given that cell division is an important factor in hepatocyte function, we studied hepatocyte metabolic capacity in vitro. Stem cell-derived hepatocytes were examined for cytochrome P450 expression using well characterized antisera. CYP2D6 and CYP3A expression was detected in 84.4% (± 2.1%) and 95.4% (± 2.6%) of HLCs derived on Matrigel ([Figures 5](#fig5){ref-type="fig"}A and 5B). On laminin 521, 85.7% (± 5.7%) of cells expressed CYP2D6 and 91.3% (± 3.7%) expressed CYP3A ([Figures 5](#fig5){ref-type="fig"}A and 5B). On the laminin 111 mix, 82.5% (± 5.0%) cells were positive for CYP2D6, and 90.6% (± 2.9%) of cells were positive for CYP3A ([Figures 5](#fig5){ref-type="fig"}A and 5B). Although protein expression appeared to be equivalent, stem cell-derived hepatocyte CYP P450 function varied ([Figure 5](#fig5){ref-type="fig"}C). On the laminin 111 mix, CYP1A2 activity increased over time and was significantly higher than on Matrigel at all time points. On laminin 521, CYP1A2 was elevated at all time points and was significantly greater than on Matrigel cultures on days 24 and 26 of differentiation. CYP3A function was increased up to 25-fold on the laminin 111 mix ([Figure 5](#fig5){ref-type="fig"}C). HLCs on both laminins exhibited significantly increased metabolic function relative to cells on Matrigel at all time points. To corroborate these data, differentiation experiments were carried out in another hESC line, Manchester 12, available at GMP-grade ([Figure S4](#mmc1){ref-type="supplementary-material"}). The results obtained demonstrate that HLCs derived from Manchester 12 (Man12) on both laminins displayed significantly superior CYP3A and CYP1A2 function in comparison with Matrigel cultures ([Figure S4](#mmc1){ref-type="supplementary-material"}).

Following this, stem cell-derived hepatocyte function was compared with cryopreserved adult hepatocytes. Primary hepatocyte function varied between male and female samples (continuous versus dotted line in [Figure 5](#fig5){ref-type="fig"}C). CYP1A2 function was comparable between primary hepatocytes and HLCs generated on the laminin 111 mix ([Figure 5](#fig5){ref-type="fig"}C; [Figure S3](#mmc1){ref-type="supplementary-material"}C), whereas CYP3A function was significantly superior to primary hepatocytes in HLCs differentiated on both laminins ([Figure 5](#fig5){ref-type="fig"}C; [Figure S3](#mmc1){ref-type="supplementary-material"}C). Although both H9- and Man12-derived hepatocytes displayed improved function on laminin 521 and the laminin 111 mix, H9-derived hepatocytes were closer in terms of metabolic activity to cryopreserved human hepatocytes ([Figure 5](#fig5){ref-type="fig"}; [Figure S4](#mmc1){ref-type="supplementary-material"}). Despite these changes in metabolic capacity, we did not detect any significant differences in albumin or α fetoprotein secretion by ELISA ([Figure S2](#mmc1){ref-type="supplementary-material"}). This was in contrast to another hESC line, Manchester 11 (Man11). Man11-derived hepatocytes did not demonstrate improved cytochrome P450 activities on laminin 521 and the 111 mix. However, they did demonstrate organized features and significantly reduced AFP secretion when compared with Matrigel, demonstrating a reduction of fetal-like behavior. In support of this, Man11-derived populations also displayed significantly increased albumin secretion on laminin 521 in comparison with Matrigel and the laminin 111 mix ([Figure S5](#mmc1){ref-type="supplementary-material"}).

Human Embryonic Stem Cell-Derived Hepatocyte Organization {#sec2.5}
---------------------------------------------------------

HLCs derived on laminin 521 and the laminin 111 mix displayed a more primary hepatocyte-like appearance with very pronounced nuclei that were often bi-nucleate ([Figure 6](#fig6){ref-type="fig"}A). Phase contrast images also indicated that hepatocytes were arranged in organized structures within the culture dish. Around these hepatic clusters, an important basal membrane marker was detected, multidrug resistance-associated protein (MRP-1). Only hepatocytes differentiated on laminins 521 and the laminin 111 mix exhibited networks of organized hepatocytes expressing MRP1 in vitro. This was in stark contrast to cells on Matrigel, which displayed more individual and punctate staining ([Figure 6](#fig6){ref-type="fig"}B). To determine whether cell organization improved canalicular function, we examined biliary efflux using 5(6)-carboxy-2′,7′-dichlorofluorescein diacetate (CDFDA). Notably, cell organization was paralleled by more active biliary efflux in cells differentiated on laminin 521 and the laminin 111 mix versus Matrigel ([Figure 6](#fig6){ref-type="fig"}C).

Genome-wide Analysis {#sec2.6}
--------------------

The experiments presented so far demonstrated an improvement in stem cell differentiation to hepatocytes on laminins. To understand which gene regulatory networks underpinned this, we performed an extensive and unbiased bioinformatics analysis ([Figure 7](#fig7){ref-type="fig"}). For this purpose, hESCs were differentiated on Matrigel ([@bib13]), laminin 521, and the laminin 111 mix. The standard differentiation protocol was applied, and whole-genome expression profiles of three independent experiments were analyzed. Data were compared with a previous study ([@bib13]) that used freshly isolated primary human hepatocytes (FHs), hESC cells, and Matrigel-differentiated HLCs (day 17 and 21). These data were compared with stem cell-derived hepatocytes derived on Matrigel, laminin 521, and the laminin 111 mix on day 24 of the differentiation process (day 24, L521 and L111, respectively).

The overview by principal component analysis illustrates that laminin-directed differentiation shifted HLCs toward FHs ([Figure 7](#fig7){ref-type="fig"}A). The number of differentially expressed genes in this study (556 between Matrigel and laminin 521 and 664 between Matrigel and the laminin 111 mix, false discovery rate \[FDR\] adjusted) could be considered major. To further characterize this difference, we employed CellNet software ([@bib2]; [Figure 7](#fig7){ref-type="fig"}B). Consistent with previous studies ([@bib13], [@bib29]), CellNet identified repression of stem cell gene regulatory network scores (GRN-ESC) and increased liver and colon GRNs in stem cell-derived hepatocytes ([Figure 7](#fig7){ref-type="fig"}B). Importantly, CellNet demonstrated a significant decrease of the hESC- and colon-associated GRNs in laminin- versus Matrigel-differentiated samples ([Figure 7](#fig7){ref-type="fig"}B; [Figure S6](#mmc1){ref-type="supplementary-material"}). Of the two laminins, the laminin 111 mix showed a significantly stronger effect than pure laminin 521 ([Figure 7](#fig7){ref-type="fig"}B). To obtain further insights, we used a recently published fuzzy clustering technique ([@bib13]). In the proliferation- and cell migration-associated clusters, laminins led to a significantly stronger suppression than Matrigel cultures (clusters III--V; [Figure 7](#fig7){ref-type="fig"}C). These results were confirmed by qPCR with a reduction in E2F7, AURKA, SOX11, and TFAP2A on laminin versus Matrigel ([Figure S6](#mmc1){ref-type="supplementary-material"}). A reduction in stem cell (SALL2 and LIN28A) and fibroblast (FOXF2) gene expression was also detected by qPCR. In summary, the main advantage of laminin over Matrigel was a more efficient suppression of inappropriate GRNs controlling stem cell biology, colon specification, fibroblast specification, and cell proliferation and migration ([Figure 7](#fig7){ref-type="fig"}; [Figure S6](#mmc1){ref-type="supplementary-material"}).

Given the important role of integrins as receptors for laminins and their ability to bind EGF, an important liver mitogen, we examined integrin expression and phosphatidylinositol 3-kinase (PI3K)-Akt and Jak-STAT signaling in hepatocytes replated on each ECM. In these analyses, we focused on the genes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) categories "PI3K-AKT Signaling Pathway," "JAK-STAT Signaling Pathway," and "ECM-Receptor Interaction." KEGG pathway analysis identified a significant overrepresentation of the aforementioned KEGG gene clusters in all HLCs ([Table S3](#mmc2){ref-type="supplementary-material"}; [Figure S7](#mmc1){ref-type="supplementary-material"}). From the bioinformatics analyses, we could not identify clear changes in GRNs that may be the drivers of enhanced hepatocyte differentiation on recombinant laminins ([Figure 7](#fig7){ref-type="fig"}B; [Figure S7](#mmc1){ref-type="supplementary-material"}A), and this requires more detailed investigation. Likewise, the ECMs used in our study had subtle effects on integrin expression. ITGB2 and ITGAL gene expression was downregulated in comparison with freshly isolated hepatocytes, whereas other integrins were upregulated, including ITGAV, ITGA3, and ITGB6 ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Notably, we did detect that integrins ITGA7 and ITGA6 were differentially regulated on laminin versus Matrigel, and this will be the focus of a future investigation ([Figure S7](#mmc1){ref-type="supplementary-material"}C).

Discussion {#sec3}
==========

The extracellular matrix can have profound effects on cells, modulating many biological processes, including cell attachment, migration, proliferation, differentiation repair, and development ([@bib24], [@bib25], [@bib26]). By mimicking key elements of the liver cell niche using two laminin isoforms, we dramatically improved hepatocyte differentiation, significantly enhancing cell organization and function. Although similar numbers of HLCs were produced on the three matrices, distinct differences in HLC phenotype, organization, and function were observed. Notably, CYP1A2 and 3A function were equivalent or superior to primary human hepatocytes when stem cell-derived hepatocytes were cultured on laminin 521 and the laminin 111 mix, and this remained stable for several days in culture.

In addition to metabolic function, stem cell-derived hepatocytes displayed more organized structures on the laminin substrates. The differences in cell organization between laminin and Matrigel cultures could have been underpinned by the upregulation of key proliferation and motility genes on Matrigel. With the exception of E2F7, which was reduced significantly on the laminin 111 mix only, AURKA, SOX11, and TFAP2A were reduced on both laminins. E2F7 is an important regulator of hepatocyte proliferation and human telomerase gene expression ([@bib38]) and represents a key target in the quest for a mature and stably differentiated hepatocyte in vitro. Similarly, the suppression of AURKA, SOX11, and TFAP2A, known to play key roles in cell proliferation, hyperplasia, and suppression of terminal differentiation, were also suppressed on both laminin substrates ([@bib10], [@bib17], [@bib22]), representing significant progress. Enhanced hepatocyte organization on both laminins was evidenced by MRP1 staining and resulted in improved canalicular excretion of CDFDA, suggesting a mature feature stem cell-derived hepatocytes in vitro ([@bib20]).

The analysis of liver gene expression and function suggested an improvement of the hepatocyte phenotype on laminins. We were keen to understand what underpinned this and employed gene microarrays. Using principal component analysis, our first goal was to understand whether the different matrices cause dramatic or only minor changes in overall gene expression ([@bib11], [@bib12]). The number of differentially expressed genes in this study could be considered major, with the laminin 111 mix and laminin 521 imparting three specific features on HLCs compared with Matrigel. First, expression of pluripotency-associated transcripts was more effectively suppressed by laminins. Second, the laminin 111 mix more efficiently suppressed proliferation and migration-associated gene expression. Third, induction of unwanted colon- and fibroblast-associated gene expression, which is an inherent side effect of the currently used hepatocyte differentiation protocols ([@bib13]), was ameliorated by the laminin 111 mix.

Alongside improved function and a decrease in unwanted gene expression, these laminins also provide a xeno-free alternative to Matrigel. As such, serum-free directed hepatocytes, in combination with laminin 521 or the laminin 111 mix, can now be described as "defined." To test whether our procedure was compatible with hESC lines available at clinical grade, we employed two Manchester hESC lines (Man11 and Man12). All three lines differentiated efficiently, with the majority of cells expressing albumin and CYP3A. The same level of cellular organization was also demonstrated across the GMP lines, with the HLCs on laminin 521 and the laminin 111 mix displaying networks of MRP1 staining. Notably, the H9-derived hepatocytes displayed a closer metabolic profile to primary hepatocytes than Man11- and -12-derived hepatocytes. However, both laminin 521 and the laminin 111 mix did improve the Man11 and Man12 HLC phenotype, demonstrating significant progress.

In conclusion, the efficient specification and superior performance of stem cell-derived hepatocytes on laminin substrates and their compatibility with GMP hESC lines demonstrate an important advance. We believe that our approach to hepatocyte differentiation will allow the cost-effective production of GMP-grade hepatocytes at scale that could ultimately be used in the clinic should they deemed to be fit for the purpose.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

H9, Man11, and Man12 (hESCs) were cultured as described previously ([@bib42]) and maintained in a humidified 37°C, 5% CO~2~ incubator. Human ESCs were plated onto pre-coated Matrigel, 5 μg/cm^2^ laminin 521, or 5 μg/cm^2^ laminin 111 mix (a blend of laminins 521 and 111 at a 1:3 ratio). This ratio was suggested as optimal by the laminin supplier (Biolamina). Differentiation was initiated at 40% confluence by replacing serum-free medium mTESR1 (STEMCELL Technologies) with endoderm differentiation medium: RPMI 1640 containing 1× B27 (Life Technologies), 100 ng/mL Activin A (PeproTech), and 50 ng/mL Wnt3a (R&D Systems). The medium was changed every 24 hr for 72 hr. On day 4, endoderm differentiation medium was replaced with hepatoblast differentiation medium, and this was renewed every second day for a further 5 days. The medium consisted of knockout (KO)-DMEM (Life Technologies), Serum replacement (Life Technologies), 0.5% Glutamax (Life Technologies), 1% non-essential amino acids (Life Technologies), 0.2% β-mercaptoethanol (Life Technologies), and 1% DMSO (Sigma). On day 9, differentiating cells were cultured in the hepatocyte maturation medium HepatoZYME (Life Technologies) containing 1% Glutamax (Life Technologies), supplemented with 10 ng/ml hepatocyte growth factor (PeproTech) and 20 ng/ml oncostatin m (PeproTech) as described previously ([@bib33], [@bib44]).

Primary Human Hepatocyte Culture {#sec4.2}
--------------------------------

Cryoplateable human hepatocytes (Life Technologies) were plated and maintained according to the vendor's instructions. Briefly, cryoplateable hepatocytes were resuscitated in thawing medium (CM3000) and plated onto Matrigel or laminin pre-coated 96-well plates. Cells attached to all matrices efficiently and were maintained in a humidified 37°C, 5% CO~2~ incubator. 24 hr after plating, the medium was changed to incubation medium (CM4000). 48 hr after replating, hepatocyte metabolic activity was measured using CYP3A4 and CYP1A2 pGlo technology (Promega) as described previously ([@bib44]).

Albumin and α Fetoprotein ELISA {#sec4.3}
-------------------------------

hESC-derived and cryoplateable hepatocyte αfetoprotein and albumin production was quantified using commercially available ELISA kits (Alpha Diagnostic International). The different media were collected at the denoted time points during hESC differentiation (days 20--26). Primary hepatocyte medium was harvested 24 hr after plating onto Matrigel- or laminin-coated surfaces. Samples were run in triplicate and measured on a FLUOStar Omega multi-mode microplate reader (BMG Labtech). Protein production was expressed as nanogram or microgram of protein per milliliter of medium per milligram of protein (bicinchoninic acid \[BCA\] assay, Pierce).

RNA Isolation and qPCR {#sec4.4}
----------------------

Total RNA was isolated from cells using Trizol reagent and purified in accordance with the manufacturer's instructions (Life Technologies). RNA quantification and quality were assessed using a Nanodrop system. The Superscript III reverse transcription kit (Life Technologies) was employed to prepare the cDNA. qPCR was performed with TaqMan Fast Advance Mastermix and the appropriate primer pair (Applied Biosystems) and analyzed using a Roche LightCycler 480 real-time PCR system. Gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed as relative expression over the control sample (hESC on day 0 of differentiation). qPCRs were performed in triplicate. Data analysis was performed using Roche LightCycler 480 software (version 1.5). Levels of significance were measured by Student's t test and defined as p \< 0.05.

Immunofluorescence {#sec4.5}
------------------

Throughout the differentiation process, cell cultures were fixed in 100% ice-cold methanol at −20°C for 30 min. Subsequently, fixed cells were washed twice with PBS at room temperature. Cell monolayers were blocked with 0.1% PBS-Tween containing 10% BSA for 1 hr, and subsequently the monolayers were incubated with primary antibodies diluted in PBS-0.1% Tween/1% BSA at 4°C overnight. The following day, the primary antibody was removed, and the fixed monolayers were washed three times with PBS-0.1% Tween/1% BSA. Following this, the cells were incubated with the appropriate secondary antibody diluted in PBS/0.1% Tween/1% BSA for 1 hr at room temperature and washed three times with PBS. Cultures were then mounted with PermaFluor aqueous mounting medium (Thermo Scientific) and counterstained with NucBlue Hoechst 33342 (Sigma-Aldrich). The cells were imaged with an Axio Observer Z1 microscope with LD PlanNeoFluar objective lenses (Carl Zeiss). This microscope was coupled to a Zeiss AxioCamMR3 camera used for image acquisition. The images were processed through Zeiss Axiovision SE 64 Rel 4.8, with Zeiss Axiovision version 4.9.1.0 used to analyze the images. The percentage of positive cells and SD was estimated from at least five random fields of view.

Cytochrome P450 Assays {#sec4.6}
----------------------

CYP3A and CYP1A2 activity was measured from days 16--26 using pGlo technology (Promega) and carried out according to the manufacturer's instructions for CYP450 activity estimation. CYP activity was expressed as relative light units (RLUs) per milliliter of medium per milligram of protein (BCA assay, Pierce). Levels of significance were measured by Student's t test. The experiments with hESC-derived hepatocytes are representative of six biological replicates, whereas the primary human hepatocyte experiments are representative of three biological replicates.

Functional Polarization Assay {#sec4.7}
-----------------------------

hESC-derived hepatocytes were incubated with 2 μM of CDFDA for 30 min. Cultures were then washed with ice-cold phosphate-buffered saline containing calcium and magnesium. After washing, stem cell-derived hepatocytes were counterstained with DAPI and collected for imaging. CDFDA efflux from canalicular like structures was examined microscopically.

Gene Microarray and Bioinformatics Studies {#sec4.8}
------------------------------------------

Gene microarrays and bioinformatics studies were compared and performed as described previously ([@bib13]). The extracts used in these studies pertain to day 24 stem cell-derived HLCs on Matrigel, LN521, and the LN111 mix.
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![Differentiation Protocol\
(A) Phase contrast images of representative fields of view at each key stage during differentiation (magnification, ×10). Scale bars, 100 μm.\
(B) Cell types present at differentiation stage.\
(C) Growth factors or molecules and media used at each stage. MG, Matrigel; DE, definitive endoderm; SR, serum replacement; HC, hydrocortisone.\
(D) Timescale of the process.](gr1){#fig1}

![Gene Expression during Differentiation\
(A--F) Gene expression of the pluripotency-associated markers (A) *OCT4* and (B) *NANOG*, the endoderm/hepatoblast markers (C) *FOXA2* and (D) α fetoprotein (*AFP*), (E) hepatocyte nuclear factor-4-α (*HNF4A*), and (F) albumin (*ALB*) was analyzed on days 0, 3, 9, and 18, normalized to the housekeeping gene *GAPDH*, and expressed relative to hESCs. The results shown represent three biological replicates, and error bars represent SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01; one-way ANOVA with Tukey post hoc test.](gr2){#fig2}

![Endoderm and Hepatic Specification\
(A and B) FOXA2 (A) and SOX17 (B) stained cells on MG, laminin 521, and laminin 111 on day 3 of differentiation. Cells were counterstained with Hoechst 33342. The percentage of positive cells and SD are shown. Images were taken at ×20 magnification.\
(C--E) AFP (C), HNF4a (D), and CK19 (E) on MG, laminin 521, and laminin 111 on day 9 of differentiation. Cells were counterstained with Hoechst 33342. Data are presented as the mean of three independent experiments ± SD.\
All images were taken at ×10 magnification.](gr3){#fig3}

![Hepatocyte Maturation\
(A--C) Albumin (A), E Cadherin (B), and cellular proliferation marker (Ki67, C) staining of cells on MG, laminin 521, and laminin 111 on day 18 of differentiation. Cells were counterstained with Hoechst 33342. Data are presented as the mean of three independent experiments ± SD. All images were taken at ×10 magnification.](gr4){#fig4}

![Metabolic Function and Expression\
(A and B) Expression of CYP2D6 (A) and CYP3A4 (B) on MG, LN521, and LN111 at day 24 of differentiation. Cells were counterstained with Hoechst 33342. Data are presented as the mean of three independent experiments ± SD. All images were taken at ×10 magnification.\
(C) Cytochrome P450 metabolic activity of CYP1A2 and CYP3A of cells cultured on Matrigel (black columns), laminin 521 (shaded columns), and the laminin 111 mix (white columns). Data are presented as mean of six independent experiments. Error bars represent SEM.^∗^p \< 0.05, ^∗∗^p \< 0.01; one-way ANOVA with Bonferroni post hoc analysis. The dotted and continuous lines indicates the average CYP activity of primary hepatocytes in culture. PHH(F), primary human hepatocytes, female; PHH(M), primary human hepatocytes, male.](gr5){#fig5}

![Functional Organization of Hepatocyte-like Cells\
(A) Phase contrast images of cells on day 24 of culture on MG, LN521, and LN111.\
(B) Co-immunostaining of MRP-1 (red) and of HNF4a (green).\
(C) CDFDA staining shows functional bile canaliculi on laminins, whereas, on Matrigel, only diffuse staining is seen.\
Cells were counterstained with Hoechst 33342, and all images were taken at ×10 magnification. The data presented are representative of three independent experiments.](gr6){#fig6}

![Gene Array Analysis Identifies Genome-Wide Effects of the Laminin Matrix in HLC Differentiation\
(A) Principal component analysis of the 1,000 genes with highest variance in hESCs, FHs, and HLCs differentiated on MG for 17, 21, and 24 days or L111 or L521 for 24 days. The results shown represent three biological replicates. The graph shows the two largest principal components that constitute 86.5% of the variance.\
(B) GRN status obtained from the gene expression profile in FHs, ESCs and HLCs on the different matrices. The training score for ESCs, colon, and liver are shown in dark blue and represent the maximal score for each cell/tissue. The score for the queried samples (in light blue) is calculated in relation to the maximal cell/tissue specific score, as described in [@bib2]. Significantly different scores were observed for laminin 521 and laminin 111 versus Matrigel (day 24) on ESCs and Colon GRNs (^∗∗∗^p \< 0.005, ^∗∗^p \< 0.05, ^∗^0.5, t test).\
(C) Clustering of genes with similar expression patterns in HLCs generated three superclusters representing the motifs "mature liver functions," "proliferation," and "ECM/migration" (see [Supplemental Information](#app3){ref-type="sec"} for details). Shown are the KEGG and gene ontology (GO) motifs overrepresented in each gene cluster. Representative genes for each cluster and motif are also indicated. Genes in cluster V were expressed at lower levels on HLCs in laminin 111 compared with Matrigel. See [Table S3](#mmc2){ref-type="supplementary-material"} for a full list of gene and motif enrichment analyses in each gene cluster. Data are presented as the mean of three independent experiments. significant differences in mean gene expression levels (log2 scale) were observed between Matrigel (day 24), laminin 521, and laminin 111 in clusters 5, 10, and 6, which correspond to the supercluster proliferation (t test, p \< 0.005).](gr7){#fig7}
